Page last updated: 2024-08-25

rosiglitazone and Cryptogenic Fibrosing Alveolitis

rosiglitazone has been researched along with Cryptogenic Fibrosing Alveolitis in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Caporarello, N; Choi, KM; Haak, AJ; Jones, DL; Ligresti, G; Manlove, LJ; Meridew, JA; Prakash, YS; Tan, Q; Tschumperlin, DJ1

Other Studies

1 other study(ies) available for rosiglitazone and Cryptogenic Fibrosing Alveolitis

ArticleYear
PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state.
    Thorax, 2019, Volume: 74, Issue:8

    Topics: Actins; Animals; beta-Galactosidase; Bleomycin; Cell Line; Cellular Senescence; Collagen Type I; Collagen Type I, alpha 1 Chain; Cyclin-Dependent Kinase Inhibitor p16; Fibroblasts; Fibronectins; Gene Expression; Gene Knockdown Techniques; Humans; Hypoglycemic Agents; Idiopathic Pulmonary Fibrosis; Mice; Mitochondria; NAD; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Primary Cell Culture; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Triiodothyronine

2019